Lambers Heerspink, Hiddo J2; Chertow, Glenn M3; Akizawa, Tadao3; Audhya, Paul3; Bakris, George L3; Goldsberry, Angie3; Krauth, Melissa3; Linde, Peter Wilhelm Lund4; McMurray, John J3; Meyer, Colin J3; Parving, Hans-Henrik1; Remuzzi, Giuseppe3; Christ-Schmidt, Heidi3; Toto, Robert D3; Vaziri, Nosratola D3; Wanner, Christoph3; Wittes, Janet3; Wrolstad, Danielle3; de Zeeuw, Dick3
1 Endocrinology, Department of, Abdominal Centre, Rigshospitalet, The Capital Region of Denmark2 Department of Clinical Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.3 unknown4 JUR Juridisk Bacheloruddannelse
the Occurrence of renal eveNts (BEACON) trial
Type 2 diabetes mellitus (T2DM) is the most important contributing cause of end-stage renal disease (ESRD) worldwide. Bardoxolone methyl, a nuclear factor-erythroid-2-related factor 2 activator, augments estimated glomerular filtration. The Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial was designed to establish whether bardoxolone methyl slows or prevents progression to ESRD. Herein, we describe baseline characteristics of the BEACON population.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association, 2013, Vol 28, Issue 11, p. 2841-50